-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Patients -X- _ O
with -X- _ O
influenza -X- _ O
complicated -X- _ O
with -X- _ O
pneumonia -X- _ O
are -X- _ O
at -X- _ O
high -X- _ O
risk -X- _ O
of -X- _ O
rapid -X- _ O
progression -X- _ O
to -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
( -X- _ O
ARDS -X- _ O
) -X- _ O
. -X- _ O
Prone -X- _ B-Intervention
positioning -X- _ I-Intervention
with -X- _ O
longer -X- _ O
duration -X- _ O
and -X- _ O
lung-protective -X- _ O
strategies -X- _ O
might -X- _ O
reduce -X- _ O
the -X- _ O
mortality -X- _ O
level -X- _ O
in -X- _ O
ARDS. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
is -X- _ O
to -X- _ O
investigate -X- _ O
the -X- _ O
survival -X- _ O
predictors -X- _ O
of -X- _ O
prone -X- _ B-Intervention
positioning -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
ARDS -X- _ I-Patient
caused -X- _ I-Patient
by -X- _ I-Patient
influenza -X- _ I-Patient
pneumonia. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
This -X- _ O
retrospective -X- _ O
study -X- _ O
was -X- _ O
conducted -X- _ O
by -X- _ O
eight -X- _ O
tertiary -X- _ O
referral -X- _ O
centers -X- _ O
in -X- _ O
Taiwan. -X- _ O
From -X- _ O
January -X- _ O
1 -X- _ O
to -X- _ O
March -X- _ O
31 -X- _ O
in -X- _ O
2016 -X- _ O
, -X- _ O
all -X- _ O
of -X- _ O
the -X- _ O
patients -X- _ O
in -X- _ O
intensive -X- _ O
care -X- _ O
units -X- _ O
with -X- _ O
virology-proven -X- _ O
influenza -X- _ O
pneumonia -X- _ O
were -X- _ O
collected -X- _ O
, -X- _ O
while -X- _ O
all -X- _ O
of -X- _ O
those -X- _ O
patients -X- _ O
with -X- _ O
ARDS -X- _ O
and -X- _ O
receiving -X- _ O
prone -X- _ B-Intervention
positioning -X- _ I-Intervention
were -X- _ O
enrolled. -X- _ O
Demographic -X- _ O
data -X- _ O
, -X- _ O
laboratory -X- _ O
examinations -X- _ O
, -X- _ O
management -X- _ O
records -X- _ O
, -X- _ O
ventilator -X- _ O
settings -X- _ O
and -X- _ O
clinical -X- _ O
outcomes -X- _ O
were -X- _ O
collected -X- _ O
for -X- _ O
analysis. -X- _ O
RESULTS -X- _ O
: -X- _ O
During -X- _ O
the -X- _ O
study -X- _ O
period -X- _ O
, -X- _ O
336 -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
influenza -X- _ O
pneumonia -X- _ O
were -X- _ O
screened -X- _ O
and -X- _ O
263 -X- _ O
patients -X- _ O
met -X- _ O
the -X- _ O
diagnosis -X- _ O
of -X- _ O
ARDS. -X- _ O
Totally -X- _ O
, -X- _ O
65 -X- _ B-Patient
patients -X- _ I-Patient
receiving -X- _ O
prone -X- _ O
positioning -X- _ O
were -X- _ O
included -X- _ O
for -X- _ O
analysis. -X- _ O
The -X- _ B-Outcome
60-day -X- _ I-Outcome
survivors -X- _ I-Outcome
had -X- _ I-Outcome
lower -X- _ I-Outcome
Acute -X- _ I-Outcome
Physiology -X- _ I-Outcome
and -X- _ I-Outcome
Chronic -X- _ I-Outcome
Health -X- _ I-Outcome
Evaluation -X- _ I-Outcome
( -X- _ I-Outcome
APACHE -X- _ I-Outcome
) -X- _ I-Outcome
II -X- _ I-Outcome
score -X- _ I-Outcome
, -X- _ I-Outcome
pneumonia -X- _ I-Outcome
severity -X- _ I-Outcome
index -X- _ I-Outcome
( -X- _ I-Outcome
PSI -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
creatinine -X- _ I-Outcome
level -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
rate -X- _ I-Outcome
of -X- _ I-Outcome
receiving -X- _ I-Outcome
renal -X- _ I-Outcome
replacement -X- _ I-Outcome
therapy -X- _ I-Outcome
than -X- _ I-Outcome
non-survivors -X- _ I-Outcome
( -X- _ I-Outcome
22.4 -X- _ I-Outcome
± -X- _ I-Outcome
8.5 -X- _ I-Outcome
vs. -X- _ I-Outcome
29.2 -X- _ I-Outcome
± -X- _ I-Outcome
7.4 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.003 -X- _ I-Outcome
; -X- _ I-Outcome
106.6 -X- _ I-Outcome
± -X- _ I-Outcome
40.9 -X- _ I-Outcome
vs. -X- _ I-Outcome
135.3 -X- _ I-Outcome
± -X- _ I-Outcome
48.6 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.019 -X- _ I-Outcome
; -X- _ I-Outcome
1.2 -X- _ I-Outcome
± -X- _ I-Outcome
0.9 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
dL -X- _ I-Outcome
vs. -X- _ I-Outcome
3.1 -X- _ I-Outcome
± -X- _ I-Outcome
3.6 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
dL -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.040 -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
4 -X- _ I-Outcome
% -X- _ I-Outcome
vs. -X- _ I-Outcome
42 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.005 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Multivariate -X- _ I-Outcome
Cox -X- _ I-Outcome
regression -X- _ I-Outcome
analysis -X- _ I-Outcome
identified -X- _ I-Outcome
PSI -X- _ I-Outcome
( -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
1.020 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
1.009–1.032 -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
renal -X- _ I-Outcome
replacement -X- _ I-Outcome
therapy -X- _ I-Outcome
( -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
6.248 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
2.245–17.389 -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
dynamic -X- _ I-Outcome
driving -X- _ I-Outcome
pressure -X- _ I-Outcome
( -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
1.372 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
1.095–1.718 -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.006 -X- _ I-Outcome
) -X- _ I-Outcome
which -X- _ I-Outcome
were -X- _ I-Outcome
independent -X- _ I-Outcome
predictors -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
60-day -X- _ I-Outcome
mortality. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
in -X- _ O
evaluating -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
prone -X- _ O
positioning -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
influenza -X- _ O
pneumonia-related -X- _ O
ARDS -X- _ O
, -X- _ O
pneumonia -X- _ B-Outcome
severity -X- _ I-Outcome
index -X- _ I-Outcome
, -X- _ I-Outcome
renal -X- _ I-Outcome
replacement -X- _ I-Outcome
therapy -X- _ I-Outcome
and -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
dynamic -X- _ I-Outcome
driving -X- _ I-Outcome
pressure -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
60-day -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
pneumonia-related -X- _ I-Outcome
ARDS -X- _ I-Outcome
receiving -X- _ I-Outcome
prone -X- _ I-Outcome
positioning. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1186 -X- _ O
/ -X- _ O
s13613-018-0440-4 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

